Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Update for the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Andrew J. Cowan, Krish Patel, Jakub Svoboda, Bijal D. Shah, Bruce D. Cheson, Georges Azzi, Viral Rabara, Lori S. Muffly, Heidi Simmons, Stephen Thuillier, Jessica T. Leonard

Blood (2023) 142 (Supplement 1): 3777.

https://doi.org/10.1182/blood-2023-187586

Published: 2023

Journal Articles

Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)

Blood (2023) 142 (Supplement 1): 2119.

https://doi.org/10.1182/blood-2023-182915

Published: 2023

Journal Articles

Thromboprophylaxis with Intermediate Dose Low Molecular Weight Heparin in Adults Undergoing Induction with L-Asparaginase for Acute Lymphoblastic Leukemia

Hong De Sa, Thomas G Deloughery, Curtis A Lachowiez, Jessica T. Leonard, Sven R. Olson, Joseph J. Shatzel, Ronan T. Swords, Elie Traer, Brandon Hayes-Lattin

Blood (2023) 142 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2023-178918

Published: 2023

Journal Articles

Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Gregory W Roloff, Ibrahim Aldoss, Noam E. Kopmar, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Nikeshan Jeyakumar, Timothy E O'Connor, Amy Zhang, Katharine Miller, Kaitlyn C Dykes, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Aaron C. Logan, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Veronika Bachanova, Wendy Stock, Ahmed Galal, Vinod Pullarkat, Ryan D Cassaday, Bijal D. Shah, Rawan Faramand, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 1030.

https://doi.org/10.1182/blood-2023-182531

Published: 2023

Journal Articles

Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment

Brandon DaSilva, Rutu D. Vyas, Alicia Darwin, Kathryn Russel, Jason Gilbert, Virginia Tan, Himani Darji, Katharine Miller, Emily C Liang, Suravi Raychaudhuri, Adam S. Duvall, Michaela Liedtke, Wendy Stock, Ryan Cassaday, Marc Schwartz, Jessica T. Leonard, Marlise R. Luskin, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 4240.

https://doi.org/10.1182/blood-2023-185176

Published: 2023

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Guru Subramanian Guru Murthy, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Adam S Duvall, Bijal D. Shah, Arielle Baim, Tyce Kearl, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2023-187721

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Blood (2023) 142 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2023-179061

Published: 2023

Journal Articles

Ex Vivo Drug Sensitivity Evaluation of a ZMYM2::FGFR1 Fusion-Positive 8p11 Myeloproliferative Syndrome (EMS) Leukemia

Sofia Beer, Jessica T. Leonard, Ariane Huang, Brian J. Druker, Cristina Tognon

Blood (2023) 142 (Supplement 1): 5794.

https://doi.org/10.1182/blood-2023-186750

Published: 2023

Journal Articles

Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Chenyu Lin, Stephanie B. Tsai, Gregory W Roloff, Amy Zhang, Ibrahim Aldoss, Noam E. Kopmar, Simone E. Dekker, Nikeshan Jeyakumar, Vishal K Gupta, Timothy E O'Connor, Kaitlyn C Dykes, Mohamed Ahmed, Bhagirathbhai Dholaria, Hector Zambrano, Danielle Bradshaw, Aaron C. Logan, Sean Tracy, Michal Kubiak, Melhem M. Solh, Santiago Mercadal, Marc Schwartz, Akash Mukherjee, Minoo Battiwalla, Paul Shaughnessy, Navneet Majhail, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Abdullah Ladha, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Joshua Sasine, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Vinod Pullarkat, Ryan D Cassaday, Katharine Miller, Lori S. Muffly, Ahmed Galal, Bijal D. Shah, Rawan Faramand

Blood (2023) 142 (Supplement 1): 3502.

https://doi.org/10.1182/blood-2023-182380

Published: 2023

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Blood (2023) 142 (Supplement 1): 1029.

https://doi.org/10.1182/blood-2023-177693

Published: 2023

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Guru Subramanian Guru Murthy, Bijal D. Shah, Adam S Duvall, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Tyce Kearl, Arielle Baim, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2023-187468

Published: 2023

Journal Articles

High Dimensional Clustering and Identification of Immune Cell Hybrid Populations in B-ALL across the Disease Continuum

Matthew Newman, Hong De Sa, Kaelan Byrd, Ranish Patel, Michael S. Parappilly, Yoko Kosaka, Evan F. Lind, Jessica T. Leonard

Blood (2023) 142 (Supplement 1): 5627.

https://doi.org/10.1182/blood-2023-180248

Published: 2023

Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2023-191166

Published: 2023

Journal Articles

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Somya Khare, Staci Williamson, Brittany O'Barr, Levanto Schachter, Andy Chen, Brandon Hayes-Lattin, Jessica T. Leonard, Amrita Desai, Peter Ferreira-Gandolfo, Denise Lackey, Kevin Christmas, Richard T Maziarz, Eneida R Nemecek

Blood (2023) 142 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2023-177864

Published: 2023

Journal Articles

Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

Noam E. Kopmar, Ted Gooley, Gregory W Roloff, Ibrahim Aldoss, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Nikeshan Jeyakumar, Timothy O'connor, Kaitlyn C Dykes, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shabaz Malik, Paul Shaughnessy, John Mathews, Aaron C. Logan, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ahmed Galal, Vinod Pullarkat, Bijal D. Shah, Rawan Faramand, Lori S. Muffly, Ryan D Cassaday

Blood (2023) 142 (Supplement 1): 522.

https://doi.org/10.1182/blood-2023-185107

Published: 2023

Journal Articles

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Ibrahim Aldoss, Rawan Faramand, Noam E. Kopmar, Kaitlyn C Dykes, Nikeshan Jeyakumar, Simone E. Dekker, Vishal K Gupta, Mohamed Ahmed, Aaron C. Logan, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shabaz Malik, John Mathews, Paul Shaughnessy, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ryan D Cassaday, Bijal D. Shah, Katharine Miller, Lori S. Muffly, Ahmed Galal, Stephanie B. Tsai, Bhagirathbhai Dholaria

Blood (2023) 142 (Supplement 1): 671.

https://doi.org/10.1182/blood-2023-182566

Published: 2023

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Jessica T. Leonard, Rachel Cook, Laura F. Newell, Arpita Gandhi, Ronan T. Swords, Christopher A. Eide, Brandon Hayes-Lattin, Kara Johnson, Elie Traer, Stephen E. Kurtz, Jennifer N. Saultz, Cristina Tognon, Jeffrey W Tyner, Curtis A. Lachowiez

Blood (2023) 142 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2023-188313

Published: 2023

Journal Articles

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Ajibade Ashaye, Yves Chalandon, Hervé Dombret, Katherine Fazioli, Bingxia Wang, Ibrahim Aldoss, Fei Huang, Jessica T. Leonard, Nora Szabo, Conor McCloskey, Sunita Nair, Mehul Dalal, Meliessa Hennessy, Tammie Yeh, Talha Badar, Hagop Kantarjian, Josep-Maria Ribera, Elias Jabbour

Blood (2023) 142 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2023-179645

Published: 2023

NARROW

Update for the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)

Thromboprophylaxis with Intermediate Dose Low Molecular Weight Heparin in Adults Undergoing Induction with L-Asparaginase for Acute Lymphoblastic Leukemia

Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Ex Vivo Drug Sensitivity Evaluation of a ZMYM2::FGFR1 Fusion-Positive 8p11 Myeloproliferative Syndrome (EMS) Leukemia

Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

High Dimensional Clustering and Identification of Immune Cell Hybrid Populations in B-ALL across the Disease Continuum

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only